A new trifocal intraocular lens (IOL) is associated with “excellent” postoperative visual outcomes at 1 month, according to researchers who presented at the American Society of Cataract and Refractive Surgery (ASCRS) 2021 meeting, held in Las Vegas July 23 to 27.
Researchers presented 1-month postoperative outcomes of patients implanted with PanOptix® (Alcon) trifocal IOLs. Outcomes included uncorrected distance visual acuity (UCDVA) mean standard error of 1-month postoperative manifest refraction and the frequency of implant change during surgery.
The cohort included 218 eyes. Mean monocular and binocular UCDVA was 20/24. Overall, 47.72% of eyes were 20/20, 84.86% were 20/25, 94.95% were 20/30, and 99.54% were 20/40 or better. Mean binocular UCDVA was 20/22, with 62.82%, 97.44%, and 100% of patients having a visual acuity of 20/20, 20/25, or 20/30 or better, respectively.
Mean monocular and binocular uncorrected near visual acuity was J1 and J1+. Overall, the mean 1-month postoperative standard error of the manifest refraction was 0.01±0.05 D.
In 130 cases (59.63%), changes were made using the Optiwave Refractive Analysis (ORA®, WaveTec) system. Only IOL power was changed in 36.92% of participants, 42.31% changed only the toric model, and 20.77% changed both.
“This new trifocal IOL delivers excellent visual outcomes at 1 month when compared to predicted refraction using ORA intraoperative aberrometry among a sample of U.S. based patients,” the researchers conclude.
Disclosure: One study author declared affiliations with the biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Hu J, Rendon A. Evaluation of a new trifocal IOL. Paper presented at: 2021 ASCRS Annual Meeting; July 2021; Las Vegas, NV. Paper 73345.